Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialPepijn Eijsvogel, Jean‐Cosme Dodart, Igor Radanović et al.|Nature Medicine|2024Cited by 38